Premium
Competing designs for phase I clinical trials: a review
Author(s) -
Rosenberger William F.,
Haines Linda M.
Publication year - 2002
Publication title -
statistics in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.996
H-Index - 183
eISSN - 1097-0258
pISSN - 0277-6715
DOI - 10.1002/sim.1229
Subject(s) - maximum tolerated dose , clinical trial , computer science , statistic , monotonic function , medical physics , phase (matter) , clinical study design , medicine , statistics , econometrics , mathematics , mathematical analysis , chemistry , organic chemistry
Phase I clinical trials are typically small, uncontrolled studies designed to determine a maximum tolerated dose of a drug which will be used in further testing. Two divergent schools have developed in designing phase I clinical trials. The first defines the maximum tolerated dose as a statistic computed from data, and hence it is identified, rather than estimated. The second defines the maximum tolerated dose as a parameter of a monotonic dose–response curve, and hence is estimated. We review techniques from both philosophies. The goal is to present these methods in a single package, to compare them from philosophical and statistical grounds, to hopefully clear up some common misconceptions, and to make a few recommendations. This paper is not a review of simulation studies of these designs, nor does it present any new simulations comparing these designs. Copyright © 2002 John Wiley & Sons, Ltd.